Thrombopoietin, interleukin-11, and early-acting megakaryocyte growth factors in human myeloid leukemia cells.
In this study we report our data on effects of early-acting megakaryocyte growth factors, particularly the c-mpl ligand also known as thrombopoietin (TPO) and interleukin-11 (IL-11), on cell proliferation and apoptosis (Apo) of primary acute myeloid leukemia (AML) cells. A proliferative response to TPO was noticed in the majority of AML samples (17/19) with an average increase of S-phase cells from 7.8% +/- 1.5 to 14.5% +/- 2.1 (p=0.0006). Resulting cell cycle activation did not always correlate with expression of the c-mpl receptor, although it was coupled, in the majority of samples, by an average decrease of apoptotic cells from 13% +/- 0.7 to 8.8% +/- 1.8 (p=0.05). Clonogenic cell growth (CFU-L) was confirmed in 5/17 of the samples with a mean colony number of 21.4 +/- 9.6 x 10(5) cells plated. Conversely, effects of IL-11 on AML cells demonstrated that cell cycle changes (recruitment from G0 to S phase) were promoted only in a minority of samples (2/14) and there was little, if any, effect on CFU-L growth (mean colony number=17.5 +/- 9.5) or Apo (from 13% +/- 0.7 to 13.3 +/- 1.9). Combination of TPO with IL-11 induced a slight increase of clonogenic cell growth, while the addition of IL-3 or SCF to the c-mpl ligand significantly raised the mean colony numbers up to 119.2 +/- 68.3 and 52.9 +/- 22.1 x 10(5) cells plated, respectively. In summary, TPO shows activity on AML cells by stimulating their proliferation in a significant proportion of cases and generally protecting the majority of AML blast cells from induction of Apo. Conversely, IL-11 exerts little effect on the cell cycle activation and Apo. These data help to understand regulation of myeloid leukemia cell growth and should be considered in the clinical use of early-acting megakaryocyte growth factors in acute leukemia.
Petrucci
M T
MT
Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza di Roma, Italia.
Ricciardi
M R
MR
Gregorj
C
C
Ariola
C
C
Mazzola
F
F
Fogli
M
M
Lemoli
R M
RM
Tafuri
A
A
D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004347:Drug Interactions; D005434:Flow Cytometry; D006133:Growth Substances / Q000494:pharmacology* / Q000502:physiology; D006801:Humans; D017370:Interleukin-11 / Q000494:pharmacology / Q000502:physiology; D007951:Leukemia, Myeloid / Q000473:pathology*; D008533:Megakaryocytes / Q000737:chemistry; D013926:Thrombopoietin / Q000494:pharmacology / Q000502:physiology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D006133:Growth Substances; D017370:Interleukin-11; D013926:Thrombopoietin